DEF 14A: Kodiak Sciences Sets Date for 2025 Annual Stockholders Meeting, Outlines Key Business Objectives

Kodiak Sciences announces its 2025 Annual Meeting of Stockholders to be held virtually on June 2, 2025, detailing proposals for director elections, executive compensation, and auditor ratification.

Summary

• Kodiak Sciences Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 2, 2025, at 9:00 a.m. Pacific Time.
• Stockholders of record as of April 7, 2025, are entitled to vote on the election of two directors, an advisory vote on executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2025.
• The company is focused on developing transformative therapeutics for retinal diseases, utilizing its ABC platform and advancing clinical programs for tarcocimab, KSI-501, and KSI-101.
• GLOW2, a Phase 3 study in diabetic retinopathy, has completed enrollment with topline data expected in 1Q 2026, while DAYBREAK, a Phase 3 study in wet AMD, is actively enrolling with topline data expected in 2Q 2026.
• Kodiak plans to file a single Biologics License Application (BLA) for tarcocimab in wet AMD, DR, and RVO, pending the results of the GLOW2 and DAYBREAK studies.
• KSI-501, an anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate, is in a Phase 3 study (DAYBREAK) for wet AMD, actively enrolling patients.
• KSI-101, a novel bispecific protein targeting IL-6 and VEGF, is in a Phase 1b study (APEX) with plans to initiate Phase 3 studies in macular edema secondary to inflammation (MESI) in 2Q 2025.
• The company is also advancing its Antibody Biopolymer Conjugate Drug (ABCD) Platform to develop therapies for glaucoma and geographic atrophy (GA).
• Kodiak ended the year with $168 million in cash and cash equivalents, which the company believes is sufficient to fund operations into 2026.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive progress in clinical trials and platform development, but also acknowledges risks inherent in forward-looking statements and the biopharmaceutical industry.

Positives

• GLOW2 has completed enrollment, and DAYBREAK is actively enrolling patients.
• Kodiak is advancing its platform technology to embed small molecules and other active pharmaceutical ingredients.
• Clinical material for both KSI-501 and KSI-101 were successfully manufactured in the first quarter of 2024.
• The company ended the year with $168 million of cash and cash equivalents, which the company believes is sufficient to fund operations into 2026.
• The company achieved progress on cost savings by subleasing corporate office space while also evaluating financing opportunities including cultivating institutional investor relationships.
• Retained key team members and expanded team capabilities to further our clinical programs, our early discovery pipeline and our technology activities.

Risks

• Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially.
• The success of clinical trials and regulatory approvals for tarcocimab, KSI-501, and KSI-101 are not guaranteed.
• The company's ability to successfully execute on its manufacturing development plan is subject to various factors.
• The development and commercialization of VETi are subject to technological and market risks.

Future Outlook

Kodiak anticipates topline data from the GLOW2 study in 1Q 2026 and from the DAYBREAK study in 2Q 2026, with plans to file a single BLA for tarcocimab in wet AMD, DR, and RVO. The company also plans to advance KSI-101 into pivotal stage studies in 2Q 2025.

Management Comments

• Victor Perlroth, M.D., Chief Executive Officer and Chairman of the Board, expressed appreciation for stockholders' interest in Kodiak.
• Dr. Perlroth stated that Kodiak is building a pipeline of potentially life transforming ophthalmology drug candidates with the goal to build a leading retinal franchise for the benefit of patients globally.

Industry Context

Kodiak Sciences is operating in the competitive biopharmaceutical industry, focusing on retinal diseases. The company's pipeline, including tarcocimab, KSI-501, and KSI-101, targets high prevalence retinal vascular diseases and inflammatory conditions, aiming to address unmet needs in extended durability and differentiated efficacy compared to existing anti-VEGF therapies.

Comparison to Industry Standards

• Kodiak Sciences is developing tarcocimab, an anti-VEGF therapy, to compete with existing agents like aflibercept (Eylea) from Regeneron and brolucizumab (Beovu) from Novartis, aiming for longer durability and flexible dosing.
• KSI-501, targeting both IL-6 and VEGF, seeks to improve outcomes in wet AMD patients, potentially surpassing the efficacy of anti-VEGF monotherapies.
• KSI-101 aims to address retinal inflammatory conditions, a market segment currently lacking intravitreal biologic therapies, differentiating it from companies focused solely on anti-VEGF treatments.
• The ABCD platform for glaucoma and geographic atrophy competes with existing therapies like complement inhibitors for GA, seeking better efficacy and extended durability.

Stakeholder Impact

• Positive impact on patients with retinal diseases through the development of new therapies.
• Potential benefits for shareholders through increased company value and stock performance.
• Commitment to ethical research and development and community support.

Next Steps

• Announce topline data for GLOW2 in 1Q 2026.
• Announce topline data for DAYBREAK in 2Q 2026.
• File a single Biologics License Application (BLA) for tarcocimab in wet AMD, DR and RVO.
• Advance KSI-101 into pivotal stage studies in MESI in 2Q 2025.
• Present additional APEX data at an Investor R&D update in June 2025.

Key Dates

Keywords

Kodiak Sciences, Annual Meeting, Tarcocimab, KSI-501, KSI-101, Retinal Diseases, Biopharmaceutical, ABC Platform, Clinical Trials, BLA, Executive Compensation, Board of Directors, PricewaterhouseCoopers, ABCD Platform, VETi